VisEn Medical, Inc.

VisEn Medical Extends Fluorescence Molecular Tomography (FMT™) Product Line

VisEn Medical Extends Fluorescence Molecular Tomography (FMT™) Product Line

September 23, 2009

New FMT 1500™ and FMT 2500™ LX Models Launched to Meet Global Demand for FMT-enabled True Quantification in Fluorescence in vivo Imaging

LS9

LS9 Secures $25 Million in Latest Round of Funding

LS9 Secures $25 Million in Latest Round of Funding

September 24, 2009

SOUTH SAN FRANCISCO, CA - September 24, 2009 - LS9, the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

Helicos BioSciences Corporation

Helicos Announces System Sale to Correlagen Diagnostics

Helicos Announces System Sale to Correlagen Diagnostics

September 28, 2009

Purchase of a Helicos® Genetic Analysis System includes collaboration on the development of targeted resequencing assays

CAMBRIDGE, Mass., Sep 28, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis.

Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates

Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates

October 6, 2009

Raises $10M to close first tranche of $25M Financing

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives Grand Challenges Explorations Grant for Innovative Global Health Research from Gates Foundation

Seventh Sense Biosystems Receives Grand Challenges Explorations Grant for Innovative Global Health Research from Gates Foundation

October 21, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems announced today that it has received a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Howard Bernstein, titled “On-skin and Intra-dermal Malaria Diagnostics with Unprecedented Simplicity of Use Based on Bio-Responsive Particles and Interstitial Fluid Analysis.”

Selecta Biosciences, Inc.

Selecta Co-Founder Named 2009 Mass High Tech All Star

Selecta Co-Founder Named 2009 Mass High Tech All Star

October 29, 2009

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company focused on discovering and developing the first generation of nanoparticle-based vaccines and immunomodulatory drugs for the treatment and prevention of human diseases, announced today that Omid Farokhzad, M.D., co-founder and Vice Chair, has been named as a 2009 Mass High Tech All Star for his contributions to the life sciences industry.

TARIS Biomedical, Inc.

TARIS Appoints Julie Lekstrom Himes, MD, to CMO Post

TARIS Appoints Julie Lekstrom Himes, MD, to CMO Post

November 6, 2009

LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the appointment of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research and operations experience within the biopharmaceutical industry, including Coley Pharmaceuticals and Millennium Pharmaceuticals. Prior to joining industry, Dr.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV

Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV

November 9, 2009

Concert Earns $12 Million Milestone from GlaxoSmithKline

CTP-518 has Potential as Unboosted HIV Protease Inhibitor

Joule Unlimited, Inc.

Joule Reports Breakthrough in Renewable Diesel Production

Joule Reports Breakthrough in Renewable Diesel Production

November 9, 2009

BIO Pacific Rim Summit – Honolulu, HI – November 9, 2009 – Joule Biotechnologies, Inc. today announced a major step forward in its development of renewable fuels, achieving direct microbial conversion of carbon dioxide (CO2) into hydrocarbons via engineered organisms, powered by solar energy.

Helicos BioSciences Corporation

Helicos BioSciences Provides Strategic Update

Helicos BioSciences Provides Strategic Update

November 9, 2009

Announces Near-Term System and Diagnostics Initiatives